spacer
home > ebr > winter 2002 > dealing with the pitfalls of intellectual property co-ownership in international biopharmaceutical r&d joint ventures
PUBLICATIONS
European Biopharmaceutical Review

Dealing with the Pitfalls of Intellectual Property Co-Ownership in International Biopharmaceutical R&D Joint Ventures

Biopharmaceutical companies increasingly join forces to research and develop new drugs and therapies. Among the many reasons for entering into collaborative R&D agreements are the sharing of risk and cost, enhanced access to complementary resources of competent research personnel, financial resources and background intellectual property (IP), as well as marketing considerations such as access to new markets. Underpinning these specific motivations is the overall objective of increasing creativity through interaction in R&D. From a legal perspective, the goal of R&D joint ventures is to create and exploit new intellectual property rights (IPRs), particularly patents (1).In this respect, ownership of IPRs often proves to be one of the most sensitive issues if it is not properly addressed at the outset of the venture. The risk of inadequate allocation of IPRs resulting from unintended joint ownership of the IPRs is indeed that these rights may not be properly used by the parties and may not be enforced against third party infringers, if the parties to the joint R&D project do not consent on the course of action to be adopted.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Thierry Calame, Attorney at Law with Lenz & Staehelin Thierry Calame is an Attorney at Law specialising in intellectual property law with Lenz & Staehelin. He represents clients in patent litigation and other IP-related litigation and advises on a wide range of IP- and technology-related commercial matters and licensing. He has a particular focus on clients in the pharmaceutical and biotechnology sectors.
Thierry holds a degree from the Swiss Federal Institute of Technology (ETH) in Chemistry and a Law degree from the University of St Gallen, Switzerland.

spacer
Thierry Calame
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 
Industry Events

CPhI Korea

21-23 August 2019, COEX, Seoul, South Korea

CPhI Korea provides a dynamic meeting place for a wide range of industry suppliers to engage with purchasers and decision makers from the pharmaceutical industry in Korea and the surrounding region. The exhibition showcases the whole pharma supply chain from ingredients, contracting services to machinery and biopharmaceuticals. It also hosts an extensive conference programme covering the latest trends and topics within the regional market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement